US 12,403,254 B2
System for interrogating serially-connected drug modules in a combinatorial drug delivery device
Martin John McLoughlin, Hillsborough, NJ (US); and Jeffrey Manfred Gunnarsson, Baltimore, MD (US)
Assigned to BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US)
Appl. No. 17/771,069
Filed by Bristol-Myers Squibb Company, Princeton, NJ (US)
PCT Filed Nov. 2, 2020, PCT No. PCT/US2020/058507
§ 371(c)(1), (2) Date Apr. 22, 2022,
PCT Pub. No. WO2021/091814, PCT Pub. Date May 14, 2021.
Claims priority of provisional application 62/932,791, filed on Nov. 8, 2019.
Prior Publication US 2022/0379024 A1, Dec. 1, 2022
Int. Cl. A61M 5/168 (2006.01); A61J 1/20 (2006.01); A61M 5/14 (2006.01); G16H 20/17 (2018.01)
CPC A61M 5/16827 (2013.01) [A61J 1/2089 (2013.01); A61M 5/1409 (2013.01); G16H 20/17 (2018.01); A61M 2205/50 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A combinatorial drug delivery device comprising:
a plurality of serially connectable modules, each of the modules including at least one drug component, wherein the modules are serially connectable to define a single flow path for the drug delivery device; and,
a master controller having a computing processing unit,
wherein, each of the modules includes:
a non-transitory memory having stored therein an address and an alphanumeric code representative of the at least one drug component contained in the corresponding drug module;
a secondary controller operatively linked to the memory of the corresponding module;
at least one communication bus connectable in series with the communication buses of the modules serially connected with the corresponding module, wherein, with the modules being serially connected, the serially-connected communication buses of the modules allow for communication signals to directly pass between the modules,
wherein, the master controller is configured to serially interrogate the secondary controllers over the serially-connected communication buses, using the addresses, to request the codes of the corresponding modules.